Trial record 1 of 700 for:    preterm birth
Previous Study | Return to List | Next Study

Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery

This study is currently recruiting participants.
Verified March 2014 by KV Pharmaceutical Company
Sponsor:
Collaborator:
ResearchPoint Global
Information provided by (Responsible Party):
KV Pharmaceutical Company
ClinicalTrials.gov Identifier:
NCT01004029
First received: October 27, 2009
Last updated: March 12, 2014
Last verified: March 2014

October 27, 2009
March 12, 2014
October 2009
June 2016   (final data collection date for primary outcome measure)
  • Determine if treatment with 17P reduces the rate of preterm birth < 35 weeks, 0 days of gestation in women with a previous singleton spontaneous preterm delivery. [ Time Frame: Delivery ] [ Designated as safety issue: No ]
    Co-primary endpoint #1
  • Determine if 17P reduces the rate of neonatal mortality or morbidity [ Time Frame: 28 days of life or discharge from the NICU ] [ Designated as safety issue: Yes ]
    Co-primary endpoint #2 Neonatal mortality or morbidity is measured by a composite index comprised of: Neonatal death, Grade 3 or 4 intraventricular hemorrhage, Respiratory distress syndrome, Bronchopulmonary dysplasia, Necrotizing enterocolitis, Proven sepsis
Determine if treatment with 17P reduces the rate of preterm birth < 35 weeks, 0 days of gestation in women with a singleton pregnancy, aged 18 years or older, with a previous singleton spontaneous preterm delivery. [ Time Frame: Delivery ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01004029 on ClinicalTrials.gov Archive Site
  • Exclude a doubling of the risk of fetal/early infant death [ Time Frame: Delivery ] [ Designated as safety issue: Yes ]
    Defined as spontaneous abortion/miscarriage (delivery from 16 weeks 0 days through 19 weeks 6 days of gestation) or neonatal death occurring in liveborns born at less than 24 weeks gestation or stillbirth (antepartum or intrapartum death from 20 weeks gestation through term), in the 17P group compared to the vehicle group
  • Preterm birth prior to 32 weeks 0 days of gestation [ Time Frame: Delivery ] [ Designated as safety issue: No ]
  • Preterm birth prior to 37 weeks 0 days of gestation [ Time Frame: Delivery ] [ Designated as safety issue: No ]
  • Neonatal death (from minutes after birth until 28 days of life) occurring in liveborns born at 24 weeks gestation or greater [ Time Frame: 28 days of life or discharge from the NICU ] [ Designated as safety issue: Yes ]
Determine if 17P reduces the rate of neonatal mortality or morbidity, if and only if, the rate of preterm birth < 35 weeks, 0 days of gestation is statistically significant (i.e., hierarchical testing approach). [ Time Frame: Delivery ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Confirmatory Study of 17P Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery
A Phase 3B, Multi-Center, Randomized, Double-Blind Study of Hydroxyprogesterone Caproate Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery

As part of the continuing effort to study the benefit and risks of 17P and preterm delivery, this study is designed as a multi-center, randomized, double-blind, vehicle-controlled clinical trial of 17P for the prevention of preterm birth prior to 35 weeks, 0 days of gestation in women with a singleton pregnancy, aged 18 years or older, with a previous singleton spontaneous preterm delivery. The study also includes a population pharmacokinetic (PK) substudy to assess the hydroxyprogesterone caproate (HPC) exposure-response relationship and the effect of body mass index (BMI) on the PK of 17P.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Preterm Birth
  • Drug: Hydroxyprogesterone Caproate Injection, 250mg/mL
    1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
    Other Names:
    • Makena
    • 17P
  • Drug: Vehicle
    Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
    Other Name: Placebo
  • Placebo Comparator: Vehicle
    Inert Oil
    Intervention: Drug: Vehicle
  • Active Comparator: Hydroxyprogesterone Caproate Injection, 250 mg/mL
    HPC 250 mg/mL in oil
    Intervention: Drug: Hydroxyprogesterone Caproate Injection, 250mg/mL
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1707
December 2016
June 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

Each subject must meet the following criteria to be enrolled in this study:

  1. Age ≥ 18 years.
  2. Singleton gestation.
  3. Project gestational age 16 weeks 0 days of gestation or more and less than or equal to 20 weeks 6 days of gestation at the time of randomization, based on clinical information and evaluation of the first ultrasound.
  4. Documented history of a previous singleton spontaneous preterm delivery. Spontaneous preterm birth is defined as delivery from 20 weeks 0 days to 36 weeks 6 days of gestation following spontaneous preterm labor or pPROM. Where possible, the gestational age of the previous preterm birth (referred to as the qualifying delivery) should be determined as described in "Gestational Age Determination". If the gestational age at delivery is obtained directly from the medical record and more than one gestational age appears, the latest will be used. As a validation of the gestational age of the previous delivery, if the infant weighed more than 3300 grams (the birth weight 90th percentile for 36 weeks gestational age), this will not qualify as preterm. The previous preterm delivery cannot be an antepartum stillbirth.

Exclusion Criteria:

  1. Multifetal gestation.
  2. Known major fetal anomaly or fetal demise. An ultrasound examination between 14 weeks 0 days through 20 weeks 3 days of gestation must be performed to rule out fetal anomalies.
  3. Progesterone treatment in any form (i.e., vaginal, oral, intramuscular) during current pregnancy, other than micronized progesterone delivered orally or vaginally provided it is stopped at least 4 weeks prior to the first dose of study medication.
  4. Heparin therapy during current pregnancy or history of thromboembolic disease.
  5. Maternal medical/obstetrical complications including:

    • Current or planned cerclage
    • Hypertension requiring medication
    • Seizure disorder
  6. Subjects with a uterine anomaly (uterine didelphys or bicornate uterus). However, subjects with uterine fibroids are eligible for the study.
  7. Unwillingness to comply with and complete the study.
  8. A 14 weeks 0 days through 20 weeks 3 days of gestation ultrasound cannot be arranged before randomization.
  9. Participation in an antenatal study in which the clinical status or intervention may influence gestational age at delivery.
  10. Participation in this trial in a previous pregnancy. Women who were screened in a previous pregnancy, but not randomized, do not have to be excluded.
  11. Known hypersensitivity to hydroxyprogesterone caproate or its components.
  12. Have any significant medical disorder that, in the opinion of the investigator, would be a contraindication to the use of the drug including those listed in section 5.3.2 of the investigational brochure. Other examples to consider include uncontrolled diabetes, known HIV infection or renal dysfunction.
  13. Have any significant medical disorder that, in the opinion of the investigator, would preclude accurate evaluation of the subject's condition or outcome in the study.
Female
18 Years and older
No
Contact: Robert Birch, PhD 314-645-6600 ext 3405 rbirch@Ther-Rx.com
United States,   Canada,   Czech Republic,   Hungary,   Italy,   Russian Federation,   Spain,   Ukraine
 
NCT01004029
17P-ES-003
Yes
KV Pharmaceutical Company
KV Pharmaceutical Company
ResearchPoint Global
Study Director: Robert Birch, PhD KV Pharmaceutical Company
KV Pharmaceutical Company
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP